

**From:** "Shuren, Jeff" <Jeff.Shuren@fda.hhs.gov>

**Date:** March 26, 2010 8:31:04 AM EDT

**To:** "Rebecca Smith-Bindman" <rebecca.smith-bindman@radiology.ucsf.edu>

**Subject: National Quality Forum**

Rebecca,

National Quality Forum adoption of a metric of CT radiation dose for purposes of quality assurance is a good idea. I believe your proposal is a reasonable starting point for improving quality, as long as it is part of a more comprehensive program. In addition, the Food and Drug Administration (FDA) is on the record as favoring facility monitoring of CTDIvol and DLP. The idea of facility monitoring of CTDIvol and DLP was the core recommendation of the FDA's initial public communication following the disclosure of over-exposures associated with CT brain perfusion scans at Cedars-Sinai Medical Center, and the concept of facility development and compliance with locally established diagnostic reference levels (DRLs) is discussed in the FDA white paper on dose reduction.

Jeff Jeffrey Shuren, M.D., J.D.

Director, Center for Devices and Radiological Health

Food and Drug Administration